HC Wainwright Reaffirms Buy Rating for CalciMedica (NASDAQ:CALC)

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 380.48% from the stock’s current price.

CalciMedica Stock Performance

CalciMedica stock opened at $3.33 on Thursday. The firm has a market cap of $35.80 million, a price-to-earnings ratio of -3.08 and a beta of 1.30. CalciMedica has a 1 year low of $2.68 and a 1 year high of $8.38. The firm’s 50 day moving average price is $4.04 and its two-hundred day moving average price is $4.54.

Insider Buying and Selling

In other news, Director Robert N. Wilson bought 54,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was bought at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the completion of the acquisition, the director now directly owns 364,196 shares in the company, valued at $1,354,809.12. This represents a 17.41 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $3.75 per share, for a total transaction of $325,751.25. Following the acquisition, the insider now directly owns 814,300 shares of the company’s stock, valued at $3,053,625. This trade represents a 11.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 312,944 shares of company stock worth $1,172,910 in the last three months. 41.55% of the stock is currently owned by insiders.

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc boosted its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the period. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.